- This topic is empty.
-
Posts
-
On December 29, the 2025 Cailian Press Eighth Investment Annual Conference, themed "Harnessing Trends · Forging Innovation," was grandly held, where the 2025 Cailian Press Capital Market Most Valuable Influence Awards were unveiled simultaneously. Kexing Biopharm successfully secured the "Most Valuable Brand Award" for its profound brand heritage and industry influence.
As an authoritative event renowned for its professional credibility in China's financial sector, the Cailian Press Investment Annual Conference has been successfully held for eight consecutive sessions. Its awards cover a wide range of industries, including technology, healthcare, and manufacturing, evaluating companies through multiple dimensions such as strategic vision, growth resilience, innovation momentum, and social value to identify industry benchmarks.
Core Strength Highlights Commercial Platform Value
Kexing Biopharm has been deeply engaged in the biopharmaceutical field for many years, focusing on therapeutic areas such as anti-tumor, autoimmune, and antiviral treatments. Addressing unmet clinical needs, the company has established cutting-edge biotechnological platforms for novel proteins, novel antibodies, and nucleic acid drugs. Adhering to a dual-driven platform-based development model of "innovation + internationalization," it is committed to becoming an innovative and international biopharmaceutical enterprise. Its marketing channels cover approximately 20,000 terminals across various provinces and regions in China, including around 8,000 tiered hospitals. Internationally, its reach extends to about 70 countries and regions, achieving 100% coverage in emerging market countries with populations exceeding 100 million. The company has also established overseas subsidiaries in Germany, Brazil, Mexico, Singapore, Colombia, Egypt, and Vietnam. Kexing Biopharm has built a tiered and progressive product portfolio consisting of self-developed commercialized products, R&D pipelines, and in-licensed products. According to Frost & Sullivan data, the core product SINOGEN® (Recombinant Human Interferon α1b Injection) accounted for approximately 55.2% of China's short-acting human interferon α1b market in 2024, maintaining the top position for six consecutive years since 2019. EPOSINO (Epoetin Alfa Injection) captured about 16.7% of China's human erythropoietin market in 2024, ranking second for four consecutive years since 2021. EPOSINO also led among similar domestic products in terms of the number of export destinations in 2024, accounting for nearly 60% of the total export value of similar Chinese products. The in-licensed product Leaptin® ranked second in China's infliximab market share in 2024. Apexelsin® (Albumin-Bound Paclitaxel for Injection) received marketing approval from the European Commission in July 2024 and accounted for 47.7% of China's albumin-bound paclitaxel export volume in the first half of 2025, securing the second position.
Sustained Innovation Forges the Long-Term Core of the Brand
Kexing Biopharm consistently prioritizes clinical needs, focusing on innovative drug pipelines in oncology and autoimmune diseases. Its dedicated "3KX" technology platform possesses end-to-end development capabilities, from target validation and candidate molecule optimization to preclinical efficacy studies and efficient clinical advancement, effectively supporting R&D and production. Notably, the "KX-BODY" antibody technology platform has achieved multiple breakthroughs in recent years. In oncology, the GB18 monoclonal antibody (targeting GDF15) for cancer cachexia has entered Phase I clinical trials, alongside the development of GB23 trispecific antibody fusion protein for solid tumors, GB27 dual-target antibody fusion protein, and GB25 bispecific tri-specific T-cell engager for colorectal cancer. In autoimmune diseases, the company focuses on major chronic conditions with large patient populations and prolonged courses requiring long-term management, such as inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE), with pipelines including the GB24 bispecific antibody and GB26 trispecific antibody. Moreover, multiple pipelines are advancing according to U.S.-China dual-submission standards, reflecting the company's internationalized upgrade in R&D innovation.
Receiving the "Most Valuable Brand Award" is both an honor and a responsibility, as well as recognition of the company's high-quality development and brand-building capabilities. Moving forward, Kexing Biopharm will continue to leverage its brand as a guide and innovation as a driver, deepen its focus on core products, actively advance R&D and innovation, and continuously enhance product quality and service levels. With an international brand image, a more competitive product portfolio, and reliable global expansion capabilities, the company aims to empower industry development and safeguard patient health.
https://www.kexingbiopharm.com/about.html
Kexing Biopharm
- You must be logged in to reply to this topic.
